The study, which has not yet been peer reviewed, tested 150 COVID-19 patients at 16 medical centers across China, the initial epicenter of the epidemic.
“When we are testing new treatments, we are looking for signals that they may work before we move on to larger studies,” Allen Cheng, infectious disease physician and professor of epidemiology in Melbourne, told Bloomberg in Australia. “This study shows no signal, so it is unlikely to be of clinical interest. “
According to the study, patients who took the drug experienced side effects, including diarrhea.
The drug was highly touted by Trump, although many health experts warned that there were not enough studies on the drug to know whether it was actually an effective treatment for COVID-19.
Since Trump’s praise for the drug, many studies on the substance have begun, including in New York State, the new epicenter of the pandemic.